Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very much appreciated sir and enjoy very much your posts here and follow accordingly. Thanks again!!
Thank you for sharing sir. Can you offer the reference you pulled this ugly inflation data from please? TIA
Added more today. IMHO, a good buying opportunity.
Ditto! (eom)
Should management screw up again on this resubmission, it may end up being a colossal disaster that will set them back 18 months and good luck finding financing. To my way of thinking, something doesn’t smell right as of this moment. Yikes!
Cancellation of Uverse 300 service took 2 phone calls speaking with hard to understand Customer Service representatives, 27 minutes of my life I will never get back. At least I will save $210/month going forward. Done and done…
I wholeheartedly agree with you. After the debacle last year, I think it would best serve the corporate team & company clear communications to investors on this mile stone and acceptance by the FDA. GLTA
Elon Musk Launches $43 Billion Hostile Takeover of Twitter
April 14, 2022, 5:19 AM CDT
Elon Musk has made a “best and final” offer to buy Twitter Inc., saying the company has extraordinary potential and he will unlock it.
The world’s richest man will pay $54.20 per share in cash, representing a 54% premium over the Jan 28. closing price and a value of about $43 billion. The social media company’s shares soared 18%.
Excellent point, thank you.
A quick question for you and other members here if I may. Regarding mRNA technology and the vaccines that both Pfizer and Moderna developed. I have received two Pfizer shots and one Pfizer booster. Would there be any potential benefit in having my second booster be Moderna? If so, why?
TIA
Nice support today in a pretty downtrodden market. Nice to see a little green!!
Agreed wholeheartedly. I’m surprised we haven’t heard much admittedly. Perhaps the media doesn’t feel it’s worth covering because there’s so much other material to focus on. Not sure.
New Covid Variant XE Found In UK, More Transmissible Than Omicron: WHO
https://www.ndtv.com/world-news/new-covid-variant-xe-found-in-uk-more-transmissible-than-omicron-who-2858643
Continued need for ENTA’s anti-viral candidate.
New Covid Variant XE Found In UK, More Transmissible Than Omicron: WHO
https://www.ndtv.com/world-news/new-covid-variant-xe-found-in-uk-more-transmissible-than-omicron-who-2858643
Wholeheartedly agree. If insiders were also purchasing I think that would bolster support and confidence in the company and future earnings. The lack of the executives buying is something to consider. Also it looks like SGMA is getting no coverage by any analysts, not that they tend to help much & may be disingenuous at times…LOL.
Thank you kindly for your response and insight. I remain surprised this decline continues. Today closed at $6.57 with a P/E of 2.81. Suspect the next quarterly update with provide a much better perspective on the “interesting” acquisition they made. Still waiting to jump in at this point. GLTA
Great perspective. One question I have is why did they acquire Wagz? Doesn’t look like is fits/compliments their primary business model.
Thank you. Fascinating to participate in this all. One or two more days up before a little pullback…before the next leg up (assuming EU remains status quo)?
Nice!!!
Thank you sir….same story I see.
GOOG chart?
Nice to hear. I am as well and bought more shares on the dip this last week. Long term “looks” great. Any downside from here IMHO would be a great buying opportunity. FWIW
Hard to believe the PE is 2.60!! Been watching this one for a while….
Been buying this last week. Apropos chips, yesterday was pretty fugly.
Thank you for the clarification, much appreciated sir.
https://ih.advfn.com/stock-market/NASDAQ/revance-therapeutics-RVNC/stock-news/87414468/securities-registration-employee-benefit-plan-s-8
Printing another plus 3 million shares…fascinating how diligent they are about taking care of themselves.
I was impressed by their earnings report this week. Do you all think a PPS Target of $330 is realistic given the Feds will increase interest rates 3-6 times this year? TIA
Thanks Flo for the heads up and guidance on COLL. My purchases were all in the mid $17’s. It’s great to appreciate the upside we’ve experienced so far!!
Muchas Gracias!!
FWIW, I suspect RVNC will raise after they RE-submit. Maybe worth a $1 bump in PPS.
Absolutely hilarious!!! I saw the news about this this morning but not the joke. Totally LOL
Progress, I guess. Maybe Foley feels good about the situation. I sure don’t. The delay is unacceptable in my book. But what do I know.
My sincere speculation at this point is they don’t have their ducks in a row. Disappointing for sure….
Very much appreciated your posts and perspectives. Please stick around.
FWIW, after the dust settles and the end of year selling takes place, I will be adding to my position. I do believe in Daxi, just less impressed with the executives. GLTA
Painfully hilarious jbog. I needed the laugh admittedly.
If I had to guess, they’re too embarrassed. What a mess and a huge disappointment for everyone.
A tad disingenuous….
RVNC gets CRL
https://investors.revance.com/news-releases/news-release-details/revance-provides-regulatory-update-daxibotulinumtoxina-injection
Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines
October 15, 2021
NASHVILLE, Tenn.--(BUSINESS WIRE)--Oct. 15, 2021-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has issued a Complete Response Letter, or CRL, regarding the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection, for the treatment of moderate to severe glabellar (frown) lines.
In a communication received on October 15, the FDA has determined it is unable to approve the BLA in its present form, and indicated that there are deficiencies related to the FDA’s onsite inspection at Revance’s manufacturing facility. Revance plans to request a Type A meeting with the FDA as soon as possible to address the deficiencies raised. No other deficiencies were identified in the CRL.
“We are very disappointed by this unanticipated response from the FDA and are seeking further clarity from the agency. We remain committed to bringing our next-generation neuromodulator product to market in both aesthetic and therapeutic indications,” said Mark Foley, President and Chief Executive Officer.
RTQ $15.02
Ouch…..guess I was wrong again.
Well stated Joe, thank you for the vote of confidence sir. Cheers, Rich